119 related articles for article (PubMed ID: 23379954)
1. Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis.
Karashima T; Fukuhara H; Tamura K; Ashida S; Kamada M; Inoue K; Taguchi T; Kuroda N; Shuin T
Int J Urol; 2013 Sep; 20(9):923-30. PubMed ID: 23379954
[TBL] [Abstract][Full Text] [Related]
2. The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.
Grépin R; Ambrosetti D; Marsaud A; Gastaud L; Amiel J; Pedeutour F; Pagès G
PLoS One; 2014; 9(3):e89449. PubMed ID: 24676409
[TBL] [Abstract][Full Text] [Related]
3. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
[TBL] [Abstract][Full Text] [Related]
4. Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma.
Karashima T; Komatsu T; Niimura M; Kawada C; Kamada M; Inoue K; Udaka K; Kuroda N; Shuin T
Int J Urol; 2014 Jul; 21(7):702-6. PubMed ID: 24571181
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine receptor kinase B silencing inhibits anoikis‑resistance and improves anticancer efficiency of sorafenib in human renal cancer cells.
Zhang P; Xing Z; Li X; Song Y; Zhao J; Xiao Y; Xing Y
Int J Oncol; 2016 Apr; 48(4):1417-25. PubMed ID: 26820170
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous metastases during an aggressive course of Xp11.2 translocation renal cell carcinoma in a teenager.
Sudour-Bonnange H; Leroy X; Chauvet MP; Classe M; Robin PM; Leblond P
Pediatr Blood Cancer; 2014 Sep; 61(9):1698-700. PubMed ID: 24585574
[TBL] [Abstract][Full Text] [Related]
7. c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature.
Zhang HL; Zhu Y; Qin XJ; Wang CF; Yao XD; Zhang SL; Dai B; Zhu YP; Shi GH; Ye DW
Clin Genitourin Cancer; 2013 Jun; 11(2):134-40. PubMed ID: 23058498
[TBL] [Abstract][Full Text] [Related]
8. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
Zheng B; Zhu H; Gu D; Pan X; Qian L; Xue B; Yang D; Zhou J; Shan Y
Biochem Biophys Res Commun; 2015 Apr; 459(2):234-239. PubMed ID: 25712526
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a renal cell carcinoma cell line derived from a human bone metastasis and establishment of an experimental nude mouse model.
Weber KL; Pathak S; Multani AS; Price JE
J Urol; 2002 Aug; 168(2):774-9. PubMed ID: 12131367
[TBL] [Abstract][Full Text] [Related]
10. Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo.
Tei H; Miyake H; Fujisawa M
Hum Cell; 2015 Jul; 28(3):114-21. PubMed ID: 25862630
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
[TBL] [Abstract][Full Text] [Related]
12. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
13. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M
Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
[TBL] [Abstract][Full Text] [Related]
14. Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient.
Shah CH; Viktorsson K; Sherif A; Kanter L; Grybäck P; Lewensohn R; Sandström P; Nilsson S; Ullén A
Anticancer Drugs; 2013 Jul; 24(6):648-52. PubMed ID: 23542751
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
Honma Y; Harada M
Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
[TBL] [Abstract][Full Text] [Related]
16. Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
El Tal AK; Remichofsky CJ; Mehregan DA; Ganger LK
Int J Dermatol; 2013 Dec; 52(12):1538-41. PubMed ID: 23676092
[No Abstract] [Full Text] [Related]
17. Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism.
Liu S; Gao M; Wang X; Ding S; Lv J; Gao D; Wang Z; Niu Z
Oncotarget; 2016 Nov; 7(48):79141-79153. PubMed ID: 27816967
[TBL] [Abstract][Full Text] [Related]
18. The significance of TIMD4 expression in clear cell renal cell carcinoma.
Yano H; Motoshima T; Ma C; Pan C; Yamada S; Nakayama T; Kitada S; Fujimoto N; Kamba T; Takeya M; Komohara Y
Med Mol Morphol; 2017 Dec; 50(4):220-226. PubMed ID: 28631038
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
[No Abstract] [Full Text] [Related]
20. RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver.
Shi JH; Liu SZ; Wierød L; Scholz H; Anmarkrud JA; Huitfeldt HS; Zhang SJ; Line PD
J Surg Oncol; 2013 Mar; 107(4):393-401. PubMed ID: 22927239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
